Reply
- PMID: 28302270
- DOI: 10.1016/j.ajo.2017.02.024
Reply
Comment on
-
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.Am J Ophthalmol. 2017 Jan;173:56-63. doi: 10.1016/j.ajo.2016.09.029. Epub 2016 Oct 1. Am J Ophthalmol. 2017. PMID: 27702624 Clinical Trial.
-
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.Am J Ophthalmol. 2017 May;177:235-236. doi: 10.1016/j.ajo.2017.02.025. Epub 2017 Mar 10. Am J Ophthalmol. 2017. PMID: 28285714 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources